Department of Medicine, Northwestern University, Chicago, Illinois.
Department of Preventive Medicine, Northwestern University, Chicago, Illinois.
JAMA Cardiol. 2017 Dec 1;2(12):1375-1379. doi: 10.1001/jamacardio.2017.3808.
Data sharing is as an expanding initiative for enhancing trust in the clinical research enterprise.
To evaluate the feasibility, process, and outcomes of a reproduction analysis of the THERMOCOOL SMARTTOUCH Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation (SMART-AF) trial using shared clinical trial data.
DESIGN, SETTING, AND PARTICIPANTS: A reproduction analysis of the SMART-AF trial was performed using the data sets, data dictionary, case report file, and statistical analysis plan from the original trial accessed through the Yale Open Data Access Project using the SAS Clinical Trials Data Transparency platform. SMART-AF was a multicenter, single-arm trial evaluating the effectiveness and safety of an irrigated, contact force-sensing catheter for ablation of drug refractory, symptomatic paroxysmal atrial fibrillation in 172 participants recruited from 21 sites between June 2011 and December 2011. Analysis of the data was conducted between December 2016 and April 2017.
Effectiveness outcomes included freedom from atrial arrhythmias after ablation and proportion of participants without any arrhythmia recurrence over the 12 months of follow-up after a 3-month blanking period. Safety outcomes included major adverse device- or procedure-related events.
The SMART AF trial participants' mean age was 58.7 (10.8) years, and 72% were men. The time from initial proposal submission to final analysis was 11 months. Freedom from atrial arrhythmias at 12 months postprocedure was similar compared with the primary study report (74.0%; 95% CI, 66.0-82.0 vs 76.4%; 95% CI, 68.7-84.1). The reproduction analysis success rate was higher than the primary study report (65.8%; 95% CI 56.5-74.2 vs 75.6%; 95% CI, 67.2-82.5). Adverse events were minimal and similar between the 2 analyses, but contact force range or regression models could not be reproduced.
The feasibility of a reproduction analysis of the SMART-AF trial was demonstrated through an academic data-sharing platform. Data sharing can be facilitated through incentivizing collaboration, sharing statistical code, and creating more decentralized data sharing platforms with fewer restrictions to data access.
数据共享是增强临床研究企业信任的一项扩展计划。
使用共享临床试验数据评估使用 THERMOCOOL SMARTTOUCH 导管治疗有症状阵发性心房颤动(SMART-AF)试验的复制分析的可行性、过程和结果。
设计、地点和参与者:使用耶鲁大学开放数据访问项目通过 SAS 临床试验数据透明平台访问的原始试验的数据集、数据字典、病例报告文件和统计分析计划,对 SMART-AF 试验进行了复制分析。SMART-AF 是一项多中心、单臂试验,评估了在 2011 年 6 月至 2011 年 12 月期间从 21 个地点招募的 172 名参与者中,用灌流、接触力感应导管治疗药物难治性、有症状阵发性心房颤动的有效性和安全性。数据分析于 2016 年 12 月至 2017 年 4 月进行。
有效性结果包括消融后无心房心律失常和在 3 个月空白期后 12 个月随访期间无任何心律失常复发的参与者比例。安全性结果包括主要不良设备或程序相关事件。
SMART AF 试验参与者的平均年龄为 58.7(10.8)岁,72%为男性。从最初的提案提交到最终分析的时间为 11 个月。术后 12 个月无心房心律失常的情况与主要研究报告相似(74.0%;95%CI,66.0-82.0 与 76.4%;95%CI,68.7-84.1)。复制分析的成功率高于主要研究报告(65.8%;95%CI,56.5-74.2 与 75.6%;95%CI,67.2-82.5)。两次分析中的不良事件均很少且相似,但无法复制接触力范围或回归模型。
通过学术数据共享平台证明了 SMART-AF 试验复制分析的可行性。可以通过激励合作、共享统计代码以及创建更多去中心化的数据共享平台来促进数据共享,这些平台对数据访问的限制较少。